RECOVERY/Phase 2 Therapeutic Trials Reconfiguration

The RECOVERY trial is jointly funded by the NIHR and UK Research and Innovation (UKRI), with research delivery supported by the NIHR's Clinical Research Network at 176 hospital sites across the UK. The trial is being coordinated by researchers at the University of Oxford, which acts as the sponsor for the research. This award is jointly funded (50:50) between the UKRI and the NIHR. The figure displayed is the total award amount of the two funders combined, with each partner contributing equally towards the project. With this support, to date the trial has recruited over 12,000 participants - making it the world's largest trial of potential COVID-19 treatments. RECOVERY/Phase 2 Therapeutic Trials Reconfiguration also known as Recovery+ is additional support to continue the work of the initial RECOVERY trial titled COVID-19: multi-arm, multi stage adaptive clinical trial (CoV-MAMS) - MC_PC_19056.